These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 30458930)

  • 21. Single- and Multiple-dose Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP1128, a Novel Peroxisome Proliferator-activated Receptor δ Modulator, in Healthy Participants.
    Taniuchi Y; van Till JWO; Wojtkowski T; Toyoshima J; Koibuchi A; Sargent B; Han D
    Clin Pharmacol Drug Dev; 2023 Aug; 12(8):810-818. PubMed ID: 36942507
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterisation of pharmacokinetics, safety and tolerability in a first-in-human study for AZD8154, a novel inhaled selective PI3Kγδ dual inhibitor targeting airway inflammatory disease.
    Sadiq MW; Asimus S; Belvisi MG; Brailsford W; Fransson R; Fuhr R; Hagberg A; Hashemi M; Jellesmark Jensen T; Jonsson J; Keen C; Körnicke T; Kristensson C; Mäenpää J; Necander S; Nemes S; Betts J
    Br J Clin Pharmacol; 2022 Jan; 88(1):260-270. PubMed ID: 34182611
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I Clinical Study of ZYAN1, A Novel Prolyl-Hydroxylase (PHD) Inhibitor to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Oral Administration in Healthy Volunteers.
    Kansagra KA; Parmar D; Jani RH; Srinivas NR; Lickliter J; Patel HV; Parikh DP; Heading H; Patel HB; Gupta RJ; Shah CY; Patel MR; Dholakia VN; Sukhadiya R; Jain MR; Parmar KV; Barot K
    Clin Pharmacokinet; 2018 Jan; 57(1):87-102. PubMed ID: 28508936
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study.
    Burris HA; Flinn IW; Patel MR; Fenske TS; Deng C; Brander DM; Gutierrez M; Essell JH; Kuhn JG; Miskin HP; Sportelli P; Weiss MS; Vakkalanka S; Savona MR; O'Connor OA
    Lancet Oncol; 2018 Apr; 19(4):486-496. PubMed ID: 29475723
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers.
    Vaughan D; Speed J; Medve R; Andrews JS
    Clin Ther; 2010 Jan; 32(1):146-60. PubMed ID: 20171420
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nonclinical and clinical pharmacological characterization of the potent and selective cathepsin K inhibitor MIV-711.
    Lindström E; Rizoska B; Henderson I; Terelius Y; Jerling M; Edenius C; Grabowska U
    J Transl Med; 2018 May; 16(1):125. PubMed ID: 29743078
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy adult male subjects.
    Shen Z; Gillen M; Miner JN; Bucci G; Wilson DM; Hall JW
    Drug Des Devel Ther; 2017; 11():2077-2086. PubMed ID: 28744099
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers.
    Darwish M; Tempero K; Kirby M; Thompson J
    Clin Ther; 2006 May; 28(5):715-24. PubMed ID: 16861093
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics, Safety, and Tolerability of Single Oral Doses of a Novel Oxytocin Receptor Antagonist-Cligosiban-in Development for Premature Ejaculation: Three Randomized Clinical Trials in Healthy Subjects.
    Osterloh IH; Muirhead GJ; Sultana S; Whaley S; van den Berg F; Atiee G
    J Sex Med; 2018 Nov; 15(11):1547-1557. PubMed ID: 30341006
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Subjects with Rheumatoid Arthritis.
    Mohamed MF; Camp HS; Jiang P; Padley RJ; Asatryan A; Othman AA
    Clin Pharmacokinet; 2016 Dec; 55(12):1547-1558. PubMed ID: 27272171
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics and pharmacodynamics of BIA 3-202, a novel COMT inhibitor, during first administration to humans.
    Almeida L; Soares-da-Silva P
    Drugs R D; 2003; 4(4):207-17. PubMed ID: 12848585
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of CH4987655 in healthy volunteers: target suppression using a biomarker.
    Lee L; Niu H; Rueger R; Igawa Y; Deutsch J; Ishii N; Mu S; Sakamoto Y; Busse-Reid R; Gimmi C; Goelzer P; De Schepper S; Yoshimura Y; Barrett J; Ishikawa Y; Weissgerber G; Peck R
    Clin Cancer Res; 2009 Dec; 15(23):7368-74. PubMed ID: 19934286
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety, tolerability, pharmacokinetics, and pharmacodynamics of fimasartan following single and repeated oral administration in the fasted and fed states in healthy subjects.
    Chi YH; Lee H; Paik SH; Lee JH; Yoo BW; Kim JH; Tan HK; Kim SL
    Am J Cardiovasc Drugs; 2011 Oct; 11(5):335-46. PubMed ID: 21910510
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Levormeloxifene: safety, pharmacodynamics and pharmacokinetics in healthy postmenopausal women following single and multiple doses of a new selective oestrogen receptor modulator.
    Skrumsager BK; Kiehr B; Pedersen PC; Gerrits M; Watson N; Bjarnason K
    Br J Clin Pharmacol; 2002 Mar; 53(3):284-95. PubMed ID: 11874392
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety, Tolerability and Pharmacokinetics of FAAH Inhibitor V158866: A Double-Blind, Randomised, Placebo-Controlled Phase I Study in Healthy Volunteers.
    Pawsey S; Wood M; Browne H; Donaldson K; Christie M; Warrington S
    Drugs R D; 2016 Jun; 16(2):181-91. PubMed ID: 26987975
    [TBL] [Abstract][Full Text] [Related]  

  • 36. First-in-Human Pharmacokinetics and Safety Study of GSK3008356, a Selective DGAT1 Inhibitor, in Healthy Volunteers.
    Okour M; Gress A; Zhu X; Rieman D; Lickliter JD; Brigandi RA
    Clin Pharmacol Drug Dev; 2019 Nov; 8(8):1088-1099. PubMed ID: 30950565
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Proof of pharmacology of Org 48775-0, a p38 MAP kinase inhibitor, in healthy volunteers.
    Moerland M; Kales AJ; Broekhuizen K; Nässander U; Nelissen R; de Kam ML; Peeters PAM; Burggraaf J
    Br J Clin Pharmacol; 2021 May; 87(5):2321-2332. PubMed ID: 33201520
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized phase I study to evaluate the safety, tolerability, pharmacokinetics and food-effect of Iguratimod in healthy adult volunteers.
    Xiao F; Zhang F; Zhang LL; Wei W
    Eur J Clin Pharmacol; 2018 Jan; 74(1):69-77. PubMed ID: 29051989
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety, tolerability and pharmacokinetics of trimebutine 3-thiocarbamoylbenzenesulfonate (GIC-1001) in a randomized phase I integrated design study: single and multiple ascending doses and effect of food in healthy volunteers.
    Paquette JM; Rufiange M; Iovu Niculita M; Massicotte J; Lefebvre M; Colin P; Telmat A; Ranger M
    Clin Ther; 2014 Nov; 36(11):1650-64. PubMed ID: 25224876
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I study on safety and pharmacokinetics of a novel influenza endonuclease inhibitor, AL-794 (JNJ-64155806), following single- and multiple-ascending doses in healthy adults.
    Kakuda TN; Yogaratnam J; Rito J; Boyce M; Mitchell T; Gupta K; Symons JA; Chanda S; Van Remoortere P; Fry J
    Antivir Ther; 2018; 23(7):555-566. PubMed ID: 29927386
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.